Skip to main content Accessibility help

Tardive dyskinesias and antipsychotics: a review

  • Pierre-Michel Llorca (a1), Isabelle Chereau (a1), Frank-Jean Bayle (a2) and Christophe Lancon (a3)


Currently, tardive dyskinesia (TD) remains an important clinical problem. The average prevalence is estimated at 30%. The appearance of antipsychotics has opened new paths. The extrapyramidal profile of these molecules is more favorable than that of conventional neuroleptics. In order to assess their prophylactic as well as curative potential, we reviewed the literature concerning four of these atypical antipsychotics: clozapine, risperidone olanzapine and amisulpride. Clozapine seems to induce fewer cases of TD than the conventional neuroleptics, and has a specific therapeutic effect. However, the risk of agranulocytosis reduces the possibility of utilisation. Risperidone appears to be an effective therapy, but several authors report cases of TD during treatment. Furthermore, larger studies and longer follow-ups are necessary to confirm the efficiency of olanzapine and amisulpride. Further studies and observations are still necessary before drawing any conclusion for these new atypical antipsychotic actions. They are doubtlessly promising, but we cannot ignore the notion of risk–benefit; regular monitoring and listening to the subjective experience of the patients must remain uppermost in the choice of therapy.


Corresponding author

*Corresponding author. Tel.: +33-4-73-75-21-24; fax: +33-4-73-75-21-26. E-mail address: (P.M. Llorca).


Hide All
1Addington, DEToewes, JAAddington, JMRisperidone and tardive dyskinesia. J. Clin. Psychiatry 1995;56:484–5.
2Ahmed, SChengappa, KNNaidu, VRBaker, RWParepally, HSchooler, NRClozapine withdraval - emergent dystonias and dyskinesias: a case series. J. Clin. Psychiatry 1988;59:472–7.
3Almeida Osvaldo, POlanzapine for the treatment of tardive dyskinesia. J. Clin. Psychiatry 7 July 1998;59:380–1.
4Anand, VSDewan, MJWithdraval-emergent dyskinesia in a patient on undergoing dosage reduction. Ann. Clin. Psychiatry 1996;8:179–82.
5Bassit, DPLouza Neto, MRClozapine efficacy in tardive dys-kinesia in schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosc. (Germany) 1998;248(4):209–11.
6Beasley, CMDellva, MATamura, RNMorgenstern, HGlazer, WMFerguson, KTollefson, GDRandomised double blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long term treatment with olanzapine or haloperidol. Br. J. Psychiatry 1999;174:23–30.
7Boyer, PLecrubier, YPoech, AJTreatment of positive and negative symptoms: pharmacologic approaches. In: Andreasen, NC editor. Schizophrenia: Positives and Negatives Symptoms and Syndromes, vol. 24. Basel, Switzerland: Karger; 2000. p. 152–74.
8Brecher, M(abstract P-15-1)Long -term safety of risperidone. Eur. Neuropsychopharmacol. 1996;6(Suppl. 3):170.
9Brecher, MJeste, DOkamoto, ALow frequency of tardive dykinesia in elderly patients with dementia exposed to risperidone for up to one year, Presented at the 37th Annual Meeting of the American college of neuropsychopharmacology. Puerto Rico: San Juan; Dec. 14-18, 1998.
10Buzan, RDRisperidone-induced tardive dyskinesia. Am. J. Psychiatry 1996;153:734–5.
11Casey, DEEffects of clozapine therapy in schizophrenie individuals at risk for tardive dyskinesia. Clozapine : a treatment option to be realized. J. Clin. Psychiatry 1998;59(Suppl 3):31–7.
12Casey, DETardive dykinesia and atypical drugs. Schizophr. Res. 1999;35:S61–6.
13Chong Siow-Ann, MRemington, GTan, CRisperidone treatment of tardive dyskinesia and dystonia. J. Clin. Psychiatry 1999;60(5):340–1.
14Chouinard, GEffects of risperidone in Tardive Dyskinesia: Analysis of the Canadian Multicenter Risperidone Study. J. Clin. Psychopharmacol 1995;15(Suppl. 1):36–44.
15Cookell, AJSpencer, CMBenfield, PAmisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia CNS Drugs 1996;6:237–56.
16Dalery, Jd’Amato, TLa schizophrénie, recherches actuelles et perspectives. Masson; 1999.
17Daniel, DGSmith, KHyde, TEgan, M(letter)Neuroleptic-induced tardive dyskinesia. Am. J. Psychiatry 1996;153: 734–734.
18Danion, JMRein, WFleurot, OImprovement of schizophrenic patients with primary negative symptoms treated with Amisulpride. Am. J. Psychiatry 1999;156(4):610–6.
19Factor, SAFriedman, JHThe emerging role of clozapine in the treatment of movement disorders. Mov. Disord. 1997;12: 483–96.
20Gerlach, JNew anti psychotics: classification, efficacy and adverse effects. Schizophr. Bull. 1991;17:289–309.
21Glazer, WReview of the incidence studies of tardive dyskinesia associated with typical antipsychotics. J. Clin. Psychiatry 2000; 61(Suppl. 4):15–20.
22Glazer, WExpected incidence of tardive dyskinesia associated with atypical antipsychotics. J. Clin. Psychiatry 2000;61(Suppl. 4):21–6.
23Jeste, DVWyatt, RJTardive dyskinesia: Reversible and persistent. Arch. Gen. Psychiatry 1979;36(5):585–90.
24Jeste, DVLacro, JPBailey, ARockwell, EHarris, MJCaligiuri, MPLower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J. Am. Geriatr. Soc. 1999;47:716–9.
25Jolley, AGHirsch, SRMcRink, AManchanda, RTrial of brief intermittent neuroleptic prophilaxis for selected schizophrenic outpatients: clinical out come at one year. Br. Med. J. 1989;298: 985–90.
26Kane, JMTardive dyskinesia. In: Jeste, DVWyatt, RJ editors. Neuropsychiatric Movement Disorders. Washington, DC: American Psychiaric Press; 1984. p. 68–95.
27Kane, JMWoermer, MLieberman, JATardive dyskinesia: Prevalence, incidence, and risk factors. Psychopharmacology 1985;2(Suppl):72–8.
28Kane, JMHonigfeld, GSinger, JClozapine for the treatment resistant schizophrenic: a double-blind comparison versus Chlopromazine/benztropine. Arch. Gen. Psychiatry 1988;45: 789–96.
29Kane, JMWoermer, MGPollak, SSafferman, AZLieberman, JADoes clozapine cause tardive dyskinesia? J. Clin. Psychiatry 1993;54:327–30.
30Kane, JMTardive dyskinesia: epidemiological and clinical presentation. In: Bloom, FEKupfer, DJ editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven press; 1995. p. 1485–96.
31Kane, JMTardive dyskinesia in affective disorders. J. Clin. Psychiatry 1999;60(Suppl. 5):43–7.
32Keck, PMcElroy, SStrakowski, SSoutullo, CAntipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J. Clin. Psychiatry 2000;61(Suppl. 4):33–8.
33Kopala, LCHoner, GWSchizophrenia and severe tardive dyskinesia responsive to risperidone. J. Clin. Psychopharmacol. 1994;14:430–1.
34Larach, Walters VZamboni, Tognolini RRueda, MHGallardo, HTorres, RDelisi, LETardive dyskinesia (TD) review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up. Schizophr. Res. 1997;28: 231–46.
35Lieberman, JASaltz, BLJohns, CAPollak, SBorenstein, MKane, JMThe effects of clozapine on tardive dyskinesia. Br. J. Psychiatry 1991;158:503–10.
36Littrell, KHJohnson, CGLittrel, SPeabody CD. Marked reduction of tardive dyskinesia with olanzapine. Arch. Gen. Psychiatry 1998;55:279–80.
37Loo, HPorier-littre, MFRein, WFleurot, OAmisulpride versus placebo in the long-term treatment of the negative symptomes of schizophrenia. Br J Psychiatry 1997;170:18–22.
38Lykouras, LYannakis, RHatzimanolis, JChristodoulou, GNTwo cases of risperidone-induced tardive dyskinesia and a review of the literature. Eur. Psychiatry 1999;14:245–7.
39Meltzer, HYClinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:18–27.
40Modestin, JStephan, PLErni, TUmari, TPrevalence of extra pyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr. Res. 2000;42:223–30.
41Morgensten, HGlazer, WMIdentifying risk-factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. Arch. Gen. Psychiatry 1993;50:723–33.
42Newton, JECannon, DJCouch, LPaige, SRReid, GMSummers, BNEffects of repeated drug holidays on serum haloperidol concentration, psychiatric symptoms and movement disorders patients. J. Clin. Psychiatry 1989;50:132–5.
43O’Brien, JBarber, RMarked improvement in tardive dyskinesia following treatment with olanzapine in a elderly subject. Br. J. Psychiatry 1998;172:186–9.
44Owens, DGCExtrapyramidal side effects and tolerability of risperidone: a review. J. Clin. Psychiatry 1994;55:29–35.
45Palliere-Martinot, MLLecubrier, YMartinot, JLAubin, FImprovement of some schizophrenia deficit symptoms with low doses of amisulpride. Am. J. Psychiatry 1995;152:130–3.
46Peacock, LSolgaard, TLublin, HGerlach, JClozapine versus typical anti psychotic: a retro and prospective study of extrapyramidal side effects. Psychopharmacology (Berlin) 1996;124: 188–96.
47Perrault, GSchoemaker, HScatton, BPlace de l’amisulpride dans la classe des neuroleptiques atypiques. L’Encephale 1996(Suppl. 11):3–8.
48Rien, WTurjanski, SClinical update on amisulpride in deficit schizophrenia. Int. Clin. Psychopharmacol. 1997;12(Suppl. 2):S19–27.
49Sherr, JDThaker, GProgression of abnormal involuntary movements during risperidone treatment. J. Clin. Psychiatry 1998;59:478–9.
50Simpson, GLee, JHShrivastava, RKClozapine in tardive dyskinesias. Psychopharmacology 1978;56:75–80.
51Simpson, GThe treatment of tardive dyskinesia ad tardive dystonia. J. Clin. Psychiatry 2000;61(Suppl. 4):39–44.
52Sotullo, CAKeck, PEElroy, SMCOlanzapine in the treatment of tardive dyskinesia : A report of two cases. J. Clin. Psychop-harmacol. 1999;19(1):100–1.
53Speller, JC Barnes TRE, Curson, DAPantelis, CAlberts, JLOne year, low-dose neuroleptic study of inpatients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride versus Haloperidol. Br. J. Psychiatry 1997;171: 564–8.
54Tamminga, CAThaker, GKMoran, MKakigi, TGao, XMClozapine in tardive dyskinesia: observations from human and animal studies. J. Clin. Psychiatry 1994;55(9 Suppl. B):120–6.
55Tollefson, GDBeasley, CMTran, PV(abstact)Olanzapine versus haloperidol: results of multicenter, international trial. Schizophr. Res. 1996;18:131.
56Waddington, JLTardive dyskinesia in schizophrenia and other disorders: Association with aging, cognitive dysfunction, and structural brain pathology in relation to neuroleptic exposure. Hum. Psychopharmacol. 1987;2:11–22.
57Woerner, MGSheitman, BBLieberman, JAKane, JMTardive dyskinesia induced by risperidone? Am. J. Psychiatry 1996;153:843.
58Wolf, MAWertenschlad, NFacteurs de risque et prévention des dyskinésies tardives. Can. J. Psychiatry 1989;34:177–81.
59Wolf, MAYassa, RLlorca, PMNeuroleptic-induced movement disorders: historical perspectives. In: Yassa, RNair, NPVJeste, D editors. Neuroleptic-inducted Movement Disorders: A Comprehensive Survey. Cambridge University Press; 1997. p. 3–9.
60Wolf, MALes dyskinésies tardives. Mosaique 2000;11:5–10.
61Yassa, RJeste, DVGender differences in tardive dyskinesia: a critical review of the literature. Schizophr. Bull. 1992;18(4): 701–15.


Tardive dyskinesias and antipsychotics: a review

  • Pierre-Michel Llorca (a1), Isabelle Chereau (a1), Frank-Jean Bayle (a2) and Christophe Lancon (a3)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Tardive dyskinesias and antipsychotics: a review

  • Pierre-Michel Llorca (a1), Isabelle Chereau (a1), Frank-Jean Bayle (a2) and Christophe Lancon (a3)
Submit a response


No Comments have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *